

WEST Search History09/269321
Att# 19

DATE: Thursday, November 07, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L3	l1 with L2	124	L3
L2	promoter	95215	L2
L1	e2f	540	L1

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 51 through 100 of 124 returned.

-
- ☐ 51. 6379927. 19 May 99; 30 Apr 02. Retinoblastoma fusion proteins. Antelman; Douglas, et al. 435/69.7; 424/192.1 530/350 530/387.1. C12P021/04 C12P021/08 C07K001/00 A61K039/00.
-
- ☐ 52. 6376215. 13 May 99; 23 Apr 02. JMY, a co-activator for p300/CBP, nucleic acid encoding JMY and uses thereof. La Thangue; Nicholas Barrie, et al. 435/69.1; 435/320.1 435/325 536/23.5. C12N015/12 C12N015/63 C12N005/06 C07H021/04.
-
- ☒ 53. 6372249. 24 Oct 94; 16 Apr 02. Senscent cell-derived inhibitors of DNA synthesis. Smith; James R., et al. 424/450; 514/12 514/2 530/350. A61K009/127 A61K038/18 C07K017/04 C07K014/475.
-
- ☐ 54. 6368809. 23 Feb 99; 09 Apr 02. E2F ubiquitination domain, and assays for inhibitors and enhancers of E2F ubiquitination. Bernards; Rene. 435/7.1; 435/183 435/320.1 435/4 536/23.5. G01N033/53.
-
- ☐ 55. 6323027. 10 Nov 98; 27 Nov 01. Common gamma chain monoclonal antibody blocking agents. Burkly; Linda C., et al. 435/334; 530/388.22. C12N005/28.
-
- ☐ 56. 6303772. 29 Mar 99; 16 Oct 01. Cyclin D binding factor, and uses thereof. Sherr; Charles J., et al. 536/23.7; 435/320.1 435/6 435/69.1 435/69.7 530/350 530/413 536/23.1 536/24.5. C07K001/22 C07K014/39 C07K014/435 C07K016/14.
-
- ☐ 57. 6303335. 10 Mar 99; 16 Oct 01. Transcription factor E2F-4. Bernards; Rene, et al. 435/69.1; 435/320.1 435/325 435/366 536/23.5. C12P021/02 C12N005/10 C12N015/12 C12N015/63.
-
- ☐ 58. 6297013. 24 Jun 99; 02 Oct 01. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription. Morgan; Antony R., et al. 435/6; 435/196 435/320.1 435/7.6 536/23.1 536/23.2 536/24.1. C12Q001/68 G01N033/53 C12N015/00 C07H021/02 C07H021/04 C07H009/16.
-
- ☐ 59. 6284880. 14 Feb 97; 04 Sep 01. Chicken embryo lethal orphan (CELO) virus GAM-1. Cotten; Matthew, et al. 536/23.5; 424/93.1 424/93.2 435/320.1 435/455 530/350. C07H021/04 C07K001/00 C12N015/00 C12N015/63.
-
- ☐ 60. 6284468. 13 Jun 00; 04 Sep 01. Composition and methods for determining the activity of DNA-binding proteins and of initiation of transcription. Morgan; Robert Charles, et al. 435/6; 435/196 435/199 435/320.1 536/23.1 536/24.1. C12Q001/68 C12N009/22 C12N009/16 C07H021/02 C07H021/04.
-
- ☐ 61. 6268334. 27 May 99; 31 Jul 01. Peptide antagonists of DP transcription factors. La Thangue; Nicholas B., et al. 514/2; 530/300. A01N037/18 A61K038/00 C01K014/00 C01K016/00 C01K017/00.
-
- ☐ 62. 6265562. 18 Dec 98; 24 Jul 01. Nucleic acid constructs whose activity is affected by inhibitors of cyclin-dependent kinases and uses thereof. Eilers; Martin, et al. 536/23.4; 536/23.1 536/23.5. C07H021/04 C07H021/02.
-

63. 6261760. 08 Mar 99; 17 Jul 01. Regulation of the cell cycle by sterols. Fielding; Christopher J., et al. 435/4; 435/7.1 435/7.2 435/7.23 436/64 536/23.5 536/24.1. C12Q001/00 G01N033/53 G01N033/567 G01N033/574 G01N033/48.
-
64. 6254862. 02 Mar 98; 03 Jul 01. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof. Little; Andrew S., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/370 435/455 435/456 435/5 435/6. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
65. 6245965. 29 Jan 99; 12 Jun 01. Knockout mice and cells that lack p19INK4d and p27KIP1 activity and methods of use thereof. Roussel; Martine F., et al. 800/18; 435/325 800/13 800/14 800/3 800/8. G01N033/00 A01K067/00 C12N015/85 C12N015/86.
-
66. 6235526. 02 May 97; 22 May 01. Nucleic acid constructs containing genes encoding transport signals. Sedlacek; Hans-Harald, et al. 435/325; 435/320.1 435/357 435/366 536/23.1 536/24.1. C12N005/10 C12N015/63.
-
67. 6221600. 08 Oct 99; 24 Apr 01. Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis. MacLeod; Michael C., et al. 435/6; 435/91.2 536/23.1 536/24.3. C12Q001/68 C12P019/34 C07H021/02 C07H021/04.
-
68. 6197756. 13 Oct 99; 06 Mar 01. Gene transfer of E2F-1 to inhibit vascular smooth muscle cell accumulation in vascular tissue. Zoldhelyi; Pierre, et al. 514/44; 435/6 435/69.1. A61K031/70 C12Q001/68 C12P021/06.
-
69. 6197293. 02 Mar 98; 06 Mar 01. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.6 435/320.1 435/325 435/366 435/371 435/375 435/455 435/456 435/5 435/6. A61K048/00 C12N015/861 C12N005/10 C12N015/63.
-
70. 6187587. 02 Mar 00; 13 Feb 01. Antisense inhibition of e2f transcription factor 1 expression. Popoff; Ian, et al. 435/375; 435/325 435/6 435/91.1 536/23.1 536/24.3 536/24.31 536/24.33 536/24.5. C07H021/04 C07H021/02 C12N015/85 C12N015/86.
-
71. 6180763. 12 Sep 97; 30 Jan 01. Cyclin D binding factor, and uses thereof. Sherr; Charles J., et al. 530/413; 435/6 435/69.1 435/69.7 435/7.92 530/324 530/325 530/326 530/327 530/328 530/329 530/330 530/350 530/358 530/403 530/412 530/417. C07K001/22.
-
72. 6165791. 24 Feb 00; 26 Dec 00. Antisense inhibition of E2F transcription factor 3 expression. Popoff; Ian, et al. 435/375; 435/325 435/6 536/23.1 536/24.3 536/24.31 536/24.5. C07H021/04 C12N015/85 C12N015/86 C12Q001/68.
-
73. 6150116. 14 May 98; 21 Nov 00. Transcription factor DP-1 antibody. La Thangue; Nicholas Barrie. 435/7.1; 435/330 435/331 435/344 530/387.1 530/387.7 530/387.9 530/388.1 530/388.8 530/389.7. G01N033/53 C12N005/06 C12N005/16 C07K016/00.
-
74. 6117638. 02 Apr 98; 12 Sep 00. Methods to screen for transcription factor-coactivator interactions. Kushner; Peter J., et al. 435/6; 435/29. C12Q001/68 C12Q001/02.
-

- ☐ 75. 6080578. 08 Dec 97; 27 Jun 00. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia. Bischoff; James R., et al. 435/325; 435/320.1 536/23.72. C07H021/04 C12N005/10.
-
- ☐ 76. 6080575. 16 Jan 98; 27 Jun 00. Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use. Heidtmann; Hans Heinrich, et al. 435/320.1; 435/456 435/464 536/23.1. C12N015/00 C12N001/12 C07H021/02.
-
- ☐ 77. 6074850. 14 Feb 97; 13 Jun 00. Retinoblastoma fusion polypeptides. Antelman; Douglas, et al. 435/69.7; 435/71.1 536/23.4. C12P021/04 C07H021/04.
-
- ☐ 78. 6048693. 16 Oct 97; 11 Apr 00. Phenotypic assays of cyclin/cyclin-dependent kinase function. Bitter; Grant A.. 435/6; 435/320.1 435/69.1 436/501 530/350 536/23.1 536/24.3 536/24.31. C12Q001/68 C12N015/63 C07H021/02 C12P021/00.
-
- ☐ 79. 6045999. 14 May 97; 04 Apr 00. Transcription factor E2F-4. Bernards; Rene, et al. 435/6; 435/69.1 435/7.1 530/300 530/350. C07K014/47 C12P021/00 C12Q001/68 G01N033/53.
-
- ☐ 80. 6034234. 17 Jul 96; 07 Mar 00. Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient. Matsuo; Ken-ichi, et al. 536/24.5; 536/23.1 536/24.1. C07H021/04.
-
- ☐ 81. 6033856. 16 Mar 98; 07 Mar 00. Promoter of the cdc25B gene, its preparation and use. Koerner; Kathrin, et al. 435/6; 435/320.1 435/325 435/357 435/366 536/23.1 536/24.1. C07H021/04 C12N005/10 C12N015/85.
-
- ☒ 82. 5981723. 05 Jun 95; 09 Nov 99. Retinoblastoma-associated protein 1 CDNA. Kaelin, Jr.; William G., et al. 536/23.5; 435/320.1 536/24.31. C12N015/12.
-
- ☐ 83. 5972706. 07 Jul 98; 26 Oct 99. Cytopathic viruses for therapy and prophylaxis of neoplasia. McCormick; Francis. 435/440; 424/93.2 424/93.3 424/93.6 435/235.1 435/236 435/320.1 514/44. C12N015/01 C12N007/04 C12N015/86 A61K031/70.
-
- ☐ 84. 5972643. 07 Jun 95; 26 Oct 99. Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor. Lobanenko; Victor L., et al. 435/69.1; 435/243 435/252.33 435/320.1 435/325 536/23.5. C12P021/02 C12N001/00 C12N001/21 C12N005/10.
-
- ☐ 85. 5885833. 13 Feb 97; 23 Mar 99. Nucleic acid constructs for the cell cycle-regulated expression of genes and therapeutic methods utilizing such constructs. Mueller; Rolf, et al. 435/372; 435/320.1 536/24.1. C12N005/10 C12N015/86.
-
- ☒ 86. 5871901. 26 Feb 96; 16 Feb 99. Assay for inhibitors of DP-1 and other DP proteins. La Thangue; Nicholas Berrie. 435/4; 435/15 435/194 435/21 435/29 435/375 530/358 530/388.24 530/389.2. C12S009/12.
-
- ☐ 87. 5871726. 26 Jun 96; 16 Feb 99. Tissue specific and tumor growth suppression by adenovirus comprising prostate specific antigen. Henderson; Daniel Robert, et al. 424/93.2; 424/93.6 435/320.1 435/325 435/456. A61K048/00 C12N005/00 C12N015/00.
-

- ☒ 88. 5869040. 07 Jun 95; 09 Feb 99. Gene therapy methods and compositions. Oin; Xiao-Oiang. 424/93.21; 435/320.1 435/366 435/69.1 536/23.5. A01N063/00.
-
- ☐ 89. 5863757. 23 Jun 95; 26 Jan 99. Transcription factor DP-1. La Thangue; Nicholas Barrie. 435/69.1; 435/320.1 435/325 536/23.5 536/24.31. C12N005/00 C12N015/00 C07H021/04.
-
- ☐ 90. 5859199. 30 Sep 96; 12 Jan 99. Transcription factor DP-3 and isoforms thereof. La Thangue; Nicholas B., et al. 530/350; 530/300 530/324. C07K014/47.
-
- ☐ 91. 5858990. 04 Mar 97; 12 Jan 99. Fas ligand compositions for treatment of proliferative disorders. Walsh; Kenneth. 514/44; 435/320.1 435/375 435/377 435/6 435/69.1. A61K048/00 C12N015/11.
-
- ☐ 92. 5856181. 14 Oct 97; 05 Jan 99. Cytopathic viruses for therapy and prophylaxis of neoplasia. McCormick; Francis. 435/325; 435/235.1 435/375 536/23.1 536/24.1. C12N005/10 C12N007/01 C07H021/04.
-
- ☐ 93. 5851806. 14 Dec 95; 22 Dec 98. Complementary adenoviral systems and cell lines. Kovessdi; Imre, et al. 435/91.41; 435/320.1 435/325 435/366 536/24.2. C12P019/34 C12N015/11 C12N005/16 C12N005/22.
-
- ☒ 94. 5846945. 07 Jun 95; 08 Dec 98. Cytopathic viruses for therapy and prophylaxis of neoplasia. McCormick; Francis. 514/44; 435/235.1 435/320.1 435/325 435/375 536/23.1 536/24.1. C12N005/10 C12N007/01 C07H021/04 A61K031/70.
-
- ☒ 95. 5821070. 20 Oct 93; 13 Oct 98. Antibodies reactive with retinoblastoma binding proteins and methods of using same. Lee; Wen-Hwa, et al. 435/7.23; 435/325 435/330 435/7.2 530/387.1 530/387.7 530/388.8 530/391.3. G01N033/574 G01N033/53 C07K016/30 C12N005/12.
-
- ☐ 96. 5801029. 07 Jun 95; 01 Sep 98. Cytopathic viruses for therapy and prophylaxis of neoplasia. McCormick; Francis. 424/93.2; 424/93.3 424/93.6 435/235.1 435/236 435/320.1 435/467 514/44. C12N015/01 C12N007/04 C12N015/86 A61K031/70.
-
- ☐ 97. 5759803. 13 May 92; 02 Jun 98. Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA. Kaelin, Jr.; William G., et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 435/69.7 530/350 530/358 536/23.4 536/23.5. C12N015/12 C07K014/435.
-
- ☐ 98. 5717058. 18 Feb 94; 10 Feb 98. Peptide inhibitors of tax-dependent transcription. Matthews; Maura-Ann H., et al. 530/328; 530/324 530/325 530/326 530/327 530/330. C07K014/155 C07K004/02 C07K005/00 C07K007/00.
-
- ☐ 99. 5705350. 29 Aug 95; 06 Jan 98. Transcription factor complexes in senescent cells. Mudryj; Maria, et al. 435/7.21; 435/15 435/194 435/6 435/7.4 436/63 436/86 530/350 530/358. C07K014/435 C12Q001/68 G01N033/50 G01N033/573.
-
- ☐ 100. 5677178. 29 Apr 96; 14 Oct 97. Cytopathic viruses for therapy and prophylaxis of neoplasia. McCormick; Francis. 435/325; 435/235.1 435/375 536/23.1 536/24.1. C12N005/10 C12N007/01 C07H021/04.
-

[Generate Collection](#)[Print](#)**Search Results - Record(s) 101 through 124 of 124 returned.**

-
- ☐ 101. [5654406](#). 14 May 96; 05 Aug 97. Antibody to ERBB2 promoter binding factor. Raziuddin, et al. 530/387.9; 530/387.3 530/388.1 536/23.5. C07K016/00 C12P021/08.
-
- ☐ 102. [5650287](#). 15 Feb 94; 22 Jul 97. Method of assaying for the oncogenic state of cells. Nevins; Joseph R., et al. 435/7.23; 435/6 435/7.1 436/63 436/64. G01N033/574 G01N033/53 G01N033/48 C12Q001/68.
-
- ☒ 103. [5518885](#). 19 Apr 94; 21 May 96. ERBB2 promoter binding protein in neoplastic disease. Raziuddin, et al. 435/6; 435/7.1. C12Q001/68 G01N033/53.
-
- ☐ 104. [5496831](#). 13 May 94; 05 Mar 96. Inhibition of insulin-induced adiposis. Alexander-Bridges; Maria C., et al. 514/290; 514/294. A01N043/42.
-
- ☐ 105. [5473056](#). 13 Oct 93; 05 Dec 95. E2F-2, a novel mammalian transcription factor. Ivey-Hoyle; Mona, et al. 530/358; 536/23.5. C07K014/47.
-
- ☐ 106. [JP 10229888 A](#). 18 Feb 98. 02 Sep 98. NUCLEIC ACID STRUCTURE FOR CELL CYCLE REGULATION AND EXPRESSION OF STRUCTURAL GENE. MUELLER, ROLF PROF DR, et al. C12N015/09; A61K031/70 A61K048/00 A61K048/00 A61K048/00 A61K048/00 A61K048/00 A61K048/00 A61K048/00 A61K048/00 A61K048/00 C12N005/10.
-
- ☐ 107. [WO 4178 A1](#). 01 Jul 99. 27 Jan 00. EXPRESSION SYSTEM CONTAINING CHIMERIC PROMOTERS WITH BINDING SITES FOR RECOMBINANT TRANSCRIPTION FACTORS. MUELLER, ROLF, et al. C12N015/85; C12N015/63 C12Q001/68.
-
- ☐ 108. [EP 859008 A2](#). 18 Feb 98. 19 Aug 98. Nucleic acid construct for the cell cycle regulated expression of structural genes. MUELLER, ROLF PROF DR, et al. C07K014/47; C12N015/85.
-
- ☐ 109. [WO 9813508 A1](#). 24 Sep 97. 02 Apr 98. METHOD OF TARGETING MALIGNANT CELLS USING AN E2F RESPONSIVE PROMOTER. FINE, HOWARD A, et al. C12N015/85; C12N015/86 C12N015/62 C12N009/12 C07K014/21 C07K019/00 A61K048/00.
-
- ☐ 110. [EP 790313 A2](#). 31 Jan 97. 20 Aug 97. Nucleic acid constructs for the cell cycle regulated expression of genes, cells comprising said constructs and their use for the preparation of medical compositions. MUELLER, ROLF PROF DR, et al. C12N015/85; C12N005/10 A61K031/70 A61K048/00.
-
- ☐ 111. [KR 2001069182 A](#) [WO 200149868 A1](#) [AU 200041472 A](#). Cancer-specific gene expression system for treating cancer without affecting normal cells, has promoter with a binding site for transcription factor E2F expressed only in cancerous cell and a structural gene. HAN, J H, et al. A61K048/00 C12N015/63 C12N015/85.
-
- ☐ 112. [WO 200104296 A1](#) [AU 9959945 A](#). Modulating cell proliferation, for treating a cell proliferation disease e.g. cancer, involves contacting the cell with a pRB pocket-binding protein or with a compound that modulates RBP1 biological activity. BRANTON, P E, et al. A61K038/17 A61K039/00

C07K014/47 C07K016/18 C12N015/12.

113. KR 2002013472 A WO 200022137 A2 AU 9963915 A BR 9914527 A NO 200101843 A EP 1121441 A2 SK 200100441 A3 CZ 200101129 A3 CN 1330715 A HU 200104107 A2. Recombinant viruses which selectively replicate in target cells used in the treatment of tumors comprise a pathway-responsive promoter linked to a viral replication repressor. RAMACHANDRA, M, et al. A61K048/00 A61P035/00 C07K014/075 C07K014/47 C12N000/00 C12N015/34 C12N015/62 C12N015/861.

114. MX 2001000018 A1 DE 19831420 A1 WO 200004178 A1 AU 9951557 A BR 9912090 A EP 1097232 A1 CN 1309716 A KR 2001071887 A. Chimeric promoter constructs with binding sites for recombinant transcription factors useful for producing agents to treat cancer, inflammation, allergy and autoimmune diseases. MUELLER, R, et al. A61K048/00 C12N005/10 C12N015/10 C12N015/11 C12N015/62 C12N015/63 C12N015/85 C12Q001/68.

115. EP 1092034 A2 WO 200001832 A2 AU 9946321 A. Activation of Gemini virus V-sense-derived promoters useful for inducing the transcription of a desired nucleotide sequence using a transcriptional inducer associated with a nematode feeding structure or site. FENOLL-COMES, C, et al. A01H005/00 C12N005/10 C12N015/67 C12N015/82 C12N015/85.

116. JP 2002516394 W WO 9960407 A1 AU 9939446 A EP 1078267 A1. Assaying for agents affecting E2F acetylation. KOUZARIDES, T. A61K038/00 A61K048/00 A61P035/00 C07K014/47 C12N015/09 C12Q001/68 G01N033/15 G01N033/50 G01N033/68.

117. CN 1197077 A EP 860445 A1. DNA construct comprising activator, chimeric promoter and structural gene - where promoter has E2F and CDF-1 protein binding sequences. LIU, N, et al. A61K038/17 A61K048/00 C07K014/47 C12N015/85.

118. US 6380170 B1 EP 859008 A2 CZ 9800460 A3 AU 9855398 A JP 10229888 A HU 9800329 A2 CA 2224123 A KR 98071443 A BR 9800641 A MX 9801277 A1 AU 735514 B. New nucleic acid construct comprises activator, chimeric promoter which binds to E2F and CDF-1 proteins and structural gene - used to treat e.g. tumours, leukaemia, cardiovascular diseases, inflammatory reactions and auto-immune disorders. LIU, N, et al. A61K031/70 A61K038/17 A61K048/00 C07K014/435 C07K014/47 C12N005/10 C12N015/09 C12N015/12 C12N015/19 C12N015/63 C12N015/85 G01N033/53.

119. US 6379927 B1 WO 9821228 A1 AU 9855899 A EP 948520 A1 BR 9712767 A CN 1244870 A US 6074850 A AU 723660 B NZ 335738 A KR 2000053323 A JP 2001503638 W MX 9904499 A1 HU 9903864 A2. New fusion polypeptide of, e.g. transcription factor - used to treat, e.g. hyper-proliferative disease such as cancer and restenosis. ANTELMAN, D, et al. A61K031/7088 A61K035/12 A61K038/00 A61K038/18 A61K039/00 A61K048/00 A61P005/00 A61P013/08 A61P017/06 A61P027/02 A61P035/00 A61P043/00 C07H021/04 C07K001/00 C07K005/00 C07K014/475 C07K014/82 C07K019/00 C12N015/09 C12P021/04 C12P021/08.

120. WO 9813508 A1 AU 9745926 A. New vectors containing E2F responsive promoter - used for specific expression of gene in malignant cells, useful for, e.g. treating glioma(s). FINE, H A, et al. A61K048/00 C07K014/21 C07K019/00 C12N009/12 C12N015/62 C12N015/85 C12N015/86.

121. AU 716500 B DE 19605274 A1 EP 790313 A2 AU 9712650 A CZ 9700418 A3 CA 2197286 A ZA 9701158 A JP 10004980 A HU 9700429 A2 US 5885833 A. Nucleic acid construct for cell-cycle

regulated gene expression - useful in gene therapy, particularly of tumours. MULLER, R, et al. A61K031/70 A61K038/18 A61K038/19 A61K048/00 C12N000/00 C12N005/10 C12N015/09 C12N015/11 C12N015/12 C12N015/18 C12N015/19 C12N015/52 C12N015/63 C12N015/74 C12N015/79 C12N015/85 C12N015/86.

☒ 122. AU 701913 B WO 9625494 A1 AU 9522215 A EP 809695 A1 JP 11500903 W.

Transcription factor E2F-5 and fragment capable of forming complex with DP protein - useful in screening assay for identification of chemotherapeutic agents for treatment of proliferative or viral disease.

BERNARDS, R, et al. A61K035/74 A61K035/76 A61K038/00 A61K038/17 A61K039/395 A61K048/00 C07K014/47 C07K016/18 C12N001/19 C12N005/10 C12N005/12 C12N015/09 C12N015/12 C12N015/81 C12P021/02 C12P021/08 C12Q001/02 G01N033/15 G01N033/577 C12N001/19 C12R001:645 C12P021/08 C12R001:91.

☐ 123. WO 9524223 A1. E2F-1 anti:sense oligo:nucleotide(s) and artificial gene contg. E2F-1 in reverse orientation - for inhibiting cell proliferation, esp. in cancers where the retino:blastoma suppressor is inactivated. CALABRETTA, B. A61K031/70 A61K031/74 A61K048/00 C07H021/00 C07H021/04 C12N015/00 C12N015/85.

☐ 124. US 5473056 A GB 2282814 A. New human transcription factor E2F-2 - involved in cell cycle regulation and useful for drug screening, also related cDNA, plasmids and transformed cells.. HEIMBROOK, D C, et al. C07K014/47 C12N015/12.

Generate Collection

Print

Terms	Documents
11 with L2	124

[Previous Page](#)

[Next Page](#)